The Diagnosis Value of a Novel Model with 5 Circulating miRNAs for Liver Fibrosis in Patients with Chronic Hepatitis B

Figure 2

Relative mRNA expression level of different plasma microRNAs in cases of the chronic hepatitis B group and control group. (a) mRNA expression of hsa-mir-1225-3p, hsa-mir-1238, hsa-miR-3162-3P, hsa-miR-4721, hsa-miR-H7, and cel-mir-39 in normal control; CHB liver fibrosis S0 patients, S1 patients, S2 patients, S3 patients, and S4 patients; and CHB compensated cirrhosis patients and CHB decompensated cirrhosis patients. (b) mRNA expression of hsa-mir-1225-3p, hsa-mir-1238, hsa-miR-3162-3P, hsa-miR-4721, hsa-miR-H7, and cel-mir-39 in the CHB nonsignificant liver fibrosis group (S0-1) and significant liver fibrosis group (S2-4).

(a)

(b)